About Aurinia

Aurinia Pharmaceuticals Is a Biopharmaceutical Company Focused on Delivering Therapies to People Living with Autoimmune Diseases with High Unmet Medical Needs

In January 2021, Aurinia introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

At Aurinia, we are passionate about changing the trajectory of autoimmune diseases. The Aurinia logo is a modern representation of the lotus flower, a symbol of life and health. Like the lotus, we are resilient in our efforts to develop breakthrough treatments that become the gold standard of patient care, enabling patients to live their fullest lives.

We are a dedicated team of experts, relentless in our pursuit of transformative therapies. Our values guide all that we do to help patients thrive.

Achieve Together

Focus on results that advance our strategy and celebrate successes to foster a culture of engagement.

Collaborate

Engage fully with others across the enterprise to achieve excellence.

Explore & Build

Empower questioning, learning and investigating purpose-driven ways to further our mission and vision.

Act Responsibly

Be accountable for all that we do to ensure the integrity of our work and our reputation.